Implementation - International best-practice care: The PREOPANC-4 project aims to safely implement the international standard of excellence for LAPC management and surgery using a multidisciplinary best-practice training program, based on the experiences of four leading international expert centers (i.e. NYU Langone Health, University of Colorado, Heidelberg University, and MD Anderson Cancer Center). We hypothesize that the PREOPANC-4 implementation project will result in the improvement in multidisciplinary patient management and selection in line with current international best-practice.
Study summary
A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021\[7\]-2030\[6\]), including a multidisciplinary training program by the four leading international expert centers.
The PREOPANC-4 project aims a safe and patient-centered implementation of the international standards of excellence for LAPC (surgery) in the Netherlands.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age 18 years or older
* Pathology-confirmed (LAPC)\*
* CT-based non-progressive disease (RECIST criteria) after at least 4 months of systemic chemotherapy (\[m\]FOLFIRINOX / gemcitabine-nab-paclitaxel).
Exclusion Criteria:
* Metastatic pancreatic cancer prior to induction chemotherapy.
* According to the Dutch Pancreatic Cancer Group (DPCG) definition: \>90 degrees arterial tumor involvement (i.e. superior mesenteric artery, celiac axis, and/or hepatic artery) and/or portovenous involvement of either \>270 degrees or occlusion.
Primary outcome measure(s)
Resection rate — Immediately after completing the inclusion period (December 31, 2024). Resection rate of the pancreatic tumor
Overall survival (OS) — After completing the follow-up period (December 31, 2029) OS from time of resection (mOS, 1-year OS \& 5-year OS)
In-hospital mortality — Yearly assessment throughout the inclusion period Mortality after resection (during primary hospitalization)
In-hospital major morbidity — Yearly assessment throughout the inclusion period Clavien-Dindo grade IIIa or higher major morbidity after resection (during primary hospitalization)
Trial sites (1)
Facility
City
Region
Status
Amsterdam UMC, locatie AMC
Amsterdam
North Holland
Recruiting
More Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
